Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report

Lenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration‐resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma.

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Case Rep
Glavni autori: Shimokihara, Kota, Kawahara, Takashi, Suzuki, Taisei, Mochizuki, Taku, Takamoto, Daiji, Teranishi, Jun‐ichi, Miyoshi, Yasuhide, Yumura, Yasushi, Yao, Masahiro, Uemura, Hiroji
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Case Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5799614/
https://ncbi.nlm.nih.gov/pubmed/29445483
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.1328
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items